截至8月6日收盘，肝炎概念下跌1.54%，位居概念板块跌幅榜前列，板块内，翰宇药业、新天药业、广 生堂等跌幅居前，股价上涨的有16只，涨幅居前的有热景生物、诚意药业、福瑞股份等，分别上涨 10.97%、5.41%、4.50%。 今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300199 | 翰宇药业 | -8.91 | 28.74 | -25626.21 | | 300436 | 广生堂 | -6.56 | 9.51 | -18934.49 | | 000766 | 通化金马 | -4.15 | 4.60 | -15856.72 | | 300158 | 振东制药 | -6.44 | 16.43 | -15325.36 | | 300009 | 安科生物 | -3.82 | 8.43 | -14850.99 | | 300122 | 智飞生物 | -2.20 | 3.29 | -13122.68 | | 002317 | 众生药业 | -3.61 | 9.12 | -1 ...

Core Viewpoint - Qianhong Pharmaceutical's stock price has experienced a slight decline, while the company is advancing its innovative drug QHRD106 through clinical trials [1] Company Overview - Qianhong Pharmaceutical is an innovative enterprise focused on the chemical pharmaceutical sector, primarily engaged in the production of heparin raw materials and formulations, as well as innovative drug research and development [1] - The company is headquartered in Jiangsu and has a product pipeline that includes original first-class new drug QHRD106 among other innovative medications [1] Clinical Development - As of August 5, 2025, QHRD106 has completed its Phase II clinical study, and the relevant materials have been submitted to the National Medical Products Administration for review [1] - The transition from Phase II to Phase III clinical trials requires meeting core conditions of safety and efficacy, along with obtaining approval from regulatory authorities [1] Market Activity - On August 5, 2025, the stock price closed at 11.38 yuan, down by 0.10 yuan from the previous trading day, with a trading volume of 653,402 hands and a transaction amount of 746 million yuan, reflecting a fluctuation of 4.79% [1] - The net outflow of main funds on that day was 40.5261 million yuan, accounting for 0.37% of the circulating market value, with a cumulative net outflow of 130.4539 million yuan over the past five trading days, representing 1.2% of the circulating market value [1]

（编辑 袁冠琳） 证券日报网讯 千红制药8月5日在互动平台回答投资者提问时表示，新药研发从二期迈入三期，首先需 要完成二期临床研究，显示药物具有良好的安全性和初步的有效性，其次将相关数据及三期临床方案递 交CDE申请沟通交流，待CDE给出明确同意意见后，方可进入三期临床研究。公司原创一类新药 QHRD106已完成二期临床研究并已将相关资料递交CDE，待CDE审核通过后，即将有序进入三期临 床。 ...

（文章来源：每日经济新闻） 千红制药（002550.SZ）8月5日在投资者互动平台表示，新药研发从二期迈入三期，首先需要完成二期 临床研究，显示药物具有良好的安全性和初步的有效性，其次将相关数据及三期临床方案递交CDE申请 沟通交流，待CDE给出明确同意意见后，方可进入三期临床研究。公司原创一类新药QHRD106已完成 二期临床研究并已将相关资料递交CDE，待CDE审核通过后，即将有序进入三期临床。 每经AI快讯，有投资者在投资者互动平台提问：投资亮点显示核心管线QHRD106进入Ⅲ期临床，这一 信息与公司官方披露是否一致？按照行业规范，一款药物从Ⅱ期进入Ⅲ期需要满足哪些核心条件？ QHRD106目前是否符合这些条件？ ...

千红制药 20250801 摘要 2019-2022 年千红制药受益于甘肃价格上涨，主要因非洲猪瘟及疫情 期间下游囤货需求旺盛。但 2023 年二季度至 2024 年二季度，甘肃价 格从 5 万元/亿单位跌至 2 万元/亿单位，严重影响业绩。 千红制药创新药管线进入收获期，106（治疗急性缺血性脑卒中）和 107（治疗难治复发急性髓系白血病）备受关注。106 预计销售峰值 40 亿元，2024 年 9 月启动三期临床，预计 2027 年初申报上市；107 是 疗效最优且研发进度最快的 CDK9 抑制剂。 千红制药主业为肝素原料药和制剂，甘肃市场增速放缓，供需平衡导致 价格处于历史底部。甘肃粗品价格随甘肃价格下滑，企业库存及周转率 影响利润率修复。公司低库存政策提升利润率。 公司曾因信托爆雷计提减值，2024 年起逐步收回信托款项并冲回，预 计 2025 年继续冲回，修复表观利润。2018-2023 年平均现金分红 1.35 亿元，平均股息率超 3%，分红政策稳定。 千红制药毛利率修复快于竞争对手，归因于低库存政策。高库存企业在 甘肃价格下行时受损，千红制药受益于低价原料。预计 2025 年半年报 毛利率达 6 ...

（文章来源：每日经济新闻） 千红制药（002550.SZ）7月30日在投资者互动平台表示，公司正有序推进方圆制药的重整投资项目，目 前正处于等待法院裁定过程中；同时，公司积极部署硫酸依替米星品种的市场推广工作，并将其纳入公 司2025年度经营管理规划及2025年度营销大纲中，目前正有序推进中。 每经AI快讯，有投资者在投资者互动平台提问：公司对方圆制药的重整预计何时完成？硫酸依替米星 的市场推广计划是否已制定？2025年销售目标是否调整？ ...

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]

New Stock Issuance - The new stock issued by Hanguo Group is priced at 15.43 RMB per share[1] - The subscription period for the tender offer of ST Kelly is from July 17, 2025, to August 15, 2025[1] Abnormal Fluctuations - Several stocks, including ST Zitian and Guangshengtang, have reported severe abnormal fluctuations[2] - The announcement links for stocks experiencing abnormal fluctuations are provided for investor reference[2] Market Updates - A total of 30 stocks have been listed for trading updates, with various announcements made between July 15 and July 21, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1]

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (July 16, 2025, July 17, 2025, and July 18, 2025) [1] - The board of directors conducted a verification regarding the abnormal trading situation and confirmed that there are no undisclosed significant information or major events in planning stages that could impact the stock [1][2] - The actual controller's concerted actor, Mr. Wang Ke, increased his shareholding by 22,000,000 shares through block trading, representing 1.72% of the company's total share capital [1] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's regulations, nor any information that could significantly affect the company's stock price [2] - The company has not identified any need to correct or supplement previously disclosed information [2]

证券代码：002550 证券简称：千红制药 公告编号：2025-020 常州千红生化制药股份有限公司 股票交易异常波动公告 2、 公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生 较大影响的未公开重大信息； 本公司及董事会全体成员保证信息披露的内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、 股票交易异常波动的情况介绍 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）股票连 续三个交易日内（2025 年 7 月 16 日、2025 年 7 月 17 日、2025 年 7 月 18 日） 日收盘价格涨幅偏离值累计超过 20％，根据《深圳证券交易所交易规则》的有关 规定，属于股票交易异常波动的情况。 二、 公司关注、核实的情况说明 针对公司股票交易异常波动情况，公司董事会就有关事项进行了核查，现就 有关情况说明如下： 1、 公司前期披露的信息不存在需要更正、补充之处； 3、 公司近期不存在经营情况及内外部经营环境发生重大变化的情形； 4、 公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重 大事项，或处于筹划阶段的重大事项； 5、 在公司本次股票异常波动期间， ...